4 August 2020 - - US-based cancer genomics company Personalis, Inc. (NASDAQ: PSNL) has launched NeXT Liquid Biopsy, a high-performance, exome-scale, tumor-profiling platform that utilizes blood samples from advanced-stage solid tumor cancer patients, the company said.

NeXT Liquid Biopsy, paired with Personalis' leading ImmunoID NeXT tissue profiling platform, enables a more comprehensive immuno-genomics view of the tumor that can now be monitored over time from blood samples.

NeXT Liquid Biopsy monitors over twenty times more genes than the majority of liquid biopsy cancer panels on the market.

These capabilities will help biopharmaceutical companies advance their understanding of tumor biology, including resistance mechanisms, to aid the development of next-generation cancer therapies.

NeXT Liquid Biopsy is immediately available for order.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response.

The Personalis ImmunoID NeXT Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample.

Personalis also provides genomic information to the VA m Veterans Program as part of their goal to sequence over a m veteran genomes.

The Personalis Clinical Laboratory is GxP aligned as well as CLIA'88-certified and CAP-accredited.